
    
      CD4-specific CAR is a chimeric antigen receptor immunotherapy treatment designed to treat
      lymphoma/leukemia expressing CD4 antigen. CD4+ T cell lymphomas are a subset of leukemias and
      lymphomas that are positive for the surface protein CD4. The purpose of this study is to
      evaluate the efficacy and safety of CD4 CAR T cells.
    
  